news
Drug Discovery Conversations: Brian Pollok, Entrepreneur-in-Residence, University of Virginia
7 July 2014 | By Oxford Global
Oxford Global Q&A Session with Brian Pollok, Entrepreneur-In-Residence, University of Virginia...
List view / Grid view
Biomarkers
Biomarkers are a naturally occurring molecule, gene, or characteristic by which a particular disease can be identified.
news
John Herrmann, CSO, Eli Lilly to Keynote at Novel Cancer Therapeutics Summit – July 7-8, 2014 Boston
29 May 2014 | By GTCBio
John Herrmann, Chief Science Officer of Global External Research & Development, Oncology at Eli Lilly To Give a Keynote Presentation on “Partnering with Lilly Oncology: Current Priorities, NYC Innovation Hub Model & Possible Future States” at the Novel Cancer Therapeutics Summit 2014...
news
Pharma R&D Europe summits series – registration closing
16 May 2014 | By Oxford Global Conferences
Registration is now closing for Oxford Global’s Pharma R&D Europe Series, the leading pharmaceutical discussion forum in Europe...
article
Drug Target Review – Issue #1 2014
9 May 2014 | By Guido Rasi, Professor Sir Mark Pepys, Kenji Schorpp et al.
We are delighted to welcome you to the inaugural issue of European Drug Target Review, a magazine focused on the changing landscape of the drug discovery industry...
article
Academia Big Pharma collaboration in drug development
Clearly what is needed is a synergistic collaboration bringing together the respective competence and expertise of academia and industry. All the major pharmaceutical companies have recognised this need and have introduced a range of different models for association with academia and small biotech or biopharma companies. Attempted solutions range from…
article
Oncology biomarkers in clinical practice – a new horizon
The ability to individualise a patient’s care has become a particularly pressing issue in the field of cancer therapeutics as there is a growing recognition that both the global incidence of cancer is steadily rising and the associated costs in terms of treatment and lost productivity are ever increasing. Advances…
